Drugmaker AstraZeneca Settles Patent Case

Drugmaker AstraZeneca Settles Patent Case

AstraZeneca said that the deal would protect its sales of the anti-cholesterol drug Crestor until 2016.

LONDON -- Anglo-Swedish pharmaceutical company AstraZeneca (IW 1000/131) on Monday said it had settled a long-running patent lawsuit over its top-selling drug Crestor.

AstraZeneca said that the deal would protect its sales of the anti-cholesterol drug until 2016.

"AstraZeneca today announced that it has entered into a settlement agreement in its US patent infringement litigation against Watson Laboratories, Inc., Actavis, Inc. (formerly known as Watson Pharmaceuticals, Inc.), and EGIS Pharmaceuticals," the company said.

Crestor generated $6.25 billion of sales in 2012, down from $6.6 billion in 2011 after losing patent protection in certain regions.

AstraZeneca's announcement comes after it last week said it was cutting 3,900 jobs -- in a major restructuring of the group over the next three years.

Copyright Agence France-Presse, 2103

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish